Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Input metadata referenced "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc., a development-stage enterprise).
Reporting Period: Quarter ended June 30, 1998 (Form 10-Q).
Business Overview: The Company is a specialty pharmaceutical firm focused on developing and commercializing pulmonary delivery technologies. It operates as a development-stage enterprise with no commercial product sales to date, relying on equity/debt financings and strategic alliances (e.g., Elan Corporation, Zambon Group) for funding and technology acquisition.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1998 | Six Months Ended June 30, 1998 | Inception to June 30, 1998 |
|---|---|---|---|
| Total Revenue | $352,562 | $353,515 | $1,817,342 |
| Net Loss | $(13,303,121) | $(15,566,169) | $(51,643,959) |
| Net Loss (Attributable to Common) | $(13,303,121) | $(15,590,069) | $(51,747,359) |
| Loss Per Share (Basic/Diluted) | $(0.67) | $(0.93) | $(9.49) |
| Cash and Cash Equivalents | $5,421,662 (as of June 30, 1998) | ||
| Total Assets | $5,961,665 (as of June 30, 1998) | ||
| Total Current Liabilities | $1,186,685 (as of June 30, 1998) | ||
| Debt | $0 (Convertible debentures fully converted to equity by June 3, 1998) |
Material Changes vs. Prior Period
- Revenue: Total revenue for the quarter was $352,562, driven primarily by $350,000 in sub-license revenue from an agreement with Zambon Group. This compares to $21,747 in the same period in 1997 (interest income only).
- Expenses: Total expenses surged to $13.66 million for the quarter (vs. $3.44 million in Q2 1997). This increase is largely due to a one-time $12.5 million charge for the acquisition of R&D in-process technology from Elan Corporation.
- Liquidity: Cash and cash equivalents increased dramatically from $393,608 at December 31, 1997, to $5,421,662 at June 30, 1998. This was fueled by $20.9 million in net cash provided by financing activities, including $17.5 million from an Elan transaction and $1.25 million from a Series B preferred stock offering.
- Debt Elimination: The Company converted all outstanding principal of its 6% convertible subordinated debentures into common stock by June 3, 1998, eliminating this liability from the balance sheet.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring operating losses for the foreseeable future as it funds product acquisition, R&D, and clinical testing. The Company believes it has sufficient liquidity to meet obligations through December 1998.
- Strategic Transactions:
- Elan Agreement: Acquired pulmonary delivery technologies for $12.5 million; Elan provided $17.5 million in funding (cash and equity) and agreed to make an additional $2 million convertible note available.
- Zambon Agreement: Sub-licensed respiratory applications of the MSI system; Zambon agreed to fund remaining development costs for these products.
- Risks:
- Going Concern: As a development-stage company, the ability to continue operations depends on securing additional capital through equity/debt offerings or licensing.
- Commercialization: No assurance that products will be successfully developed, approved by regulators, or commercialized profitably.
- Licensing Obligations: Default on payments to licensors could result in forfeiture of technology rights.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $5.4 million cash balance against the high quarterly operating loss of $13.3 million (driven by a non-cash $12.5M acquisition charge).
- Equity Dilution: Review the significant increase in outstanding shares (from ~12.6M to ~26.9M) resulting from debt conversions and recent equity financings with Elan and Zambon.
- Revenue Quality: Confirm the timing and conditions of the $350,000 sub-license revenue and the extent to which future development costs are covered by partners (Zambon/Elan).
- Subsequent Events: Note the July 1998 acquisition of the ADDS system from Aeroquip Corporation and the redemption of Series B Preferred Stock.